Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Urelumab + sintilimab + chemotherapy versus sintilimab + chemotherapy in untreated advanced non-small cell lung cancer
CTR20244671Phase 2Active
- Sponsor
- I-Mab
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of urelumab, sintilimab in non-small cell lung cancer (NSCLC), sponsored by I-Mab. Started Jan 2025; status: active.
02
Drugs
urelumabsintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20244671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244671.